Mining Real Time Tweets for Cover Picture Suggestion by Text ...
Cover Picture
1
Cover Picture Rafael Moreno, Luyong Jiang, Kerstin Moehle, Rinaldo Zurbriggen, Reinhard Glück, John A. Robinson, and Gerd Pluschke* The cover picture shows a constrained peptidomimetic of the Asn-Pro-Asn-Ala-Asn motif that is found in the major surface protein of Plasmodium falciparum sporozoites. The mimetic (bottom) is coupled through a succinate linker to a regioisomer of phosphati- dylethanolamine to afford a conjugate (top; the loop on the left represents the mimetic) that can be incorporated into immunopotentiating reconstituted influenza virosomes (IRIVs). When presented to the immune system in this form, the mimetic elicits an efficient parasite cross-reactive antibody response. The background shows immunofluorescence labeling of P. falciparum sporozoites (bright green rods). IRIVs are a form of antigen delivery that is already licensed for human clinical use so this approach may have great potential for the design and delivery of synthetic vaccines. For more details, see the article by Robinson, Pluschke, and co-workers on p. 838 ff.
-
Upload
rafael-moreno -
Category
Documents
-
view
212 -
download
0
Transcript of Cover Picture
Cover Picture
Rafael Moreno, Luyong Jiang, Kerstin Moehle, Rinaldo Zurbriggen,Reinhard Glück, John A. Robinson, and Gerd Pluschke*
The cover picture shows a constrained peptidomimetic of the Asn-Pro-Asn-Ala-Asn motifthat is found in the major surface protein of Plasmodium falciparum sporozoites. Themimetic (bottom) is coupled through a succinate linker to a regioisomer of phosphati-dylethanolamine to afford a conjugate (top; the loop on the left represents the mimetic)that can be incorporated into immunopotentiating reconstituted influenza virosomes(IRIVs). When presented to the immune system in this form, the mimetic elicits an efficientparasite cross-reactive antibody response. The background shows immunofluorescencelabeling of P. falciparum sporozoites (bright green rods). IRIVs are a form of antigendelivery that is already licensed for human clinical use so this approach may have greatpotential for the design and delivery of synthetic vaccines. For more details, see the articleby Robinson, Pluschke, and co-workers on p. 838 ff.
